References
- Blanchette VS, Key NS, Ljung L, et al.; Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost 2014;12(11): 1935–1939. doi: 10.1111/jth.12672.
- Fischer K, de Kleijn P, Negrier C, et al. The association of haemophilic arthropathy with health-related quality of life: a post hoc analysis. Haemophilia 2016; 22(6): 833–840. doi: 10.1111/hae.13120.
- Ferreira AA, Leite IC, Bustamante-Teixeira MT, et al. Health-related quality of life in hemophilia: results of the hemophilia-specific quality of life index (Haem-a-Qol) at a Brazilian blood center. Rev Bras Hematol Hemoter 2013; 35(5): 314–318. doi: 10.5581/1516-8484.20130108.
- Bastani P, Pourmohamadi K, Karimi M. Quality of life in hemophilia complicated by inhibitors. Iran Red Crescent Med J 2012; 14(4): 250–251.
- Brown TM, Lee WC, Joshi AV, Pashos CL. Health-related quality of life and productivity impact in haemophilia patients with inhibitors. Haemophilia 2009; 15(4): 911–7. doi: 10.1111/j.1365-2516.2009.02032.x.
- Chen SL. Economic costs of hemophilia and the impact of prophylactic treatment on patient management. Am J Manag Care 2016; 22(5 Suppl): s126–33.
- Rambod M, Sharif F, Molazem Z, Khair K, von Mackensen S. Health-related quality of life and psychological aspects of adults with hemophilia in Iran. Clin Appl Thromb Hemost 2018; 24(7): 1073–81. doi: 10.1177/1076029618758954.
- Forsyth AL, Witkop M, Lambing A. Associations of quality of life, pain, and self-reported arthritis with age, employment, bleed rate, and utilization of hemophilia treatment center and health care provider services: results in adults with hemophilia in the HERO study. Patient Prefer Adherence 2015; 9: 1549–60. doi: 10.2147/PPA.S87659.
- Cassis FRMY, Querol F, Forsyth A, Iorio A; HERO International Advisory Board. Psychosocial aspects of haemophilia: a systematic review of methodologies and findings. Haemophilia 2012; 18: e101–14. doi: 10.1111/j.1365-2516.2011.02683.x.
- Hartl HK, Reitter S, Eidher U, Ramschak H, Ay C, Pabinger I. The impact of severe haemophilia on the social status and quality of life among Austrian haemophiliacs. Haemophilia 2008; 14(4): 703–8. doi: 10.1111/j.1365-2516.2008.01684.x.
- Canclini M, Zanon E, Girolami A. Factors which may influence coping with disease in haemophilia patients. Haemophilia 2004; 10(5): 675. doi: 10.1111/j.1365-2516.2004.01017.x.
- Hassan TH, Badr MA, Fattah NR, Badawy SM. Assessment of musculoskeletal function and mood in haemophilia A adolescents: a cross-sectional study. Haemophilia 2011; 17(4): 683–8. doi: 10.1111/j.1365-2516.2010.02475.x.
- Kodra Y, Cavazza M, Schieppati A, et al. The social burden and quality of life of patients with haemophilia in Italy. Blood Transfus 2014; 12(3): 567–75. doi: 10.2450/2014.0042-14s.
- Handin R, Lux S, Stossel T. Blood: Principle and Practice of Hematology. 2nd edition. 2002. Philadelphia, PA: Lippincott Williams & Wilkins.
- Barr RD, Saleh M, Furlong W, et al. Health status and health-related quality of life associated with hemophilia. Am J Hematol 2002; 71(3): 152–60. doi: 10.1002/ajh.10191.
- Gringeri A, von Mackensen S. Quality of life in haemophilia. Haemophilia 2008; 14 (Suppl 3): 19–25. doi: 10.1111/j.1365-2516.2008.01709.x.
- Saulyte Trakymiene S, Steen Carlsson K. On-demand treatment in persons with severe haemophilia. Eur J Haematol Suppl 2014; 76: 39–47. doi: 10.1111/ejh.12373.
- Food and Drug Administration, US. FDA approves emicizumab-kxwh for hemophilia A with or without factor VIII inhibitors. 14 December 2018. Available from https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-emicizumab-kxwh-hemophilia-or-without-factor-viii-inhibitors (accessed 9 April 2021).
- Duncan N, Shapiro A, Ye X, Epstein J, Luo MP. Treatment patterns, health-related quality of life and adherence to prophylaxis among haemophilia A patients in the United States. Haemophilia 2012; 18(5): 760–5. doi: 10.1111/j.1365-2516.2012.02813.x.
- Lambert T, Benson G, Dolan G, et al. Practical aspects of extended half-life products for the treatment of haemophilia. Ther Adv Hematol 2018; 9(9): 295–308. doi: 10.1177/2040620718796429.
- Kootstra NA, Verma IM. Gene therapy with viral vectors. Ann Rev Pharmacol Toxicol 2003; 43(1): 413–39.
- Nathwani AC, Reiss UM, Tuddenham EGD, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med 2014; 371: 1994–2004. doi: 10.1056/NEJMoa1407309.
- Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007;357: 535–44. doi: 10.1056/NEJMoa067659.
- Pasi KJ, Rangarajan S, Mitchell N, et al. Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A. N Engl J Med 2020; 382: 29–40. doi:10.1056/NEJMoa1908490.
- Li C, Samulski RJ. Engineering adeno-associated virus vectors for gene therapy. Nat Rev Genet 2020; 21(4): 255–272. doi: 10.1038/s41576-019-0205-4.
- National Institutes of Health, Department of Health and Human Services. NIH guidelines for research involving recombinant or synthetic nucleic acid molecules (NIH guidelines). April 2019. Available from https://osp.od.nih.gov/wp-content/uploads/NIH_Guidelines.pdf (accessed 8 March 2021).
- National Institutes of Health, US National Library of Medicine. ClinicalTrials.gov. 2020. [database] Available from https://clinicaltrials.gov/ (accessed 14 April 2020).
- BioMarin Pharmaceutical. Single-arm study to evaluate the efficacy and safety of valoctocogene roxaparvovec in hemophilia A patients (BMN 270–301). Available from https://clinicaltrials.gov/ct2/show/NCT03370913 (accessed 3 September 2020).
- Rentz A, Flood E, Altisent C, et al.; Members of the HAEMOQoL-A Steering Committee. Cross-cultural development and psychometric evaluation of a patient-reported health-related quality of life questionnaire for adults with haemophilia. Haemophilia 2008; 14(5): 1023–34. doi: 10.1111/j.1365-2516.2008.01812.x.
- Chai-Adisaksopha C, Skinner MW, Curtis R, et al. Psychometric properties of the Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire. BMJ Open 2018; 8(8): e021900. doi: 10.1136/bmjopen-2018-021900.
- Chai-Adisaksopha C, Skinner MW, Curtis R, et al. Test-retest properties of the Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire and its constituent domains. Haemophilia 2019; 25(1): 75–83. doi: 10.1111/hae.13649.
- Chai-Adisaksopha C, Skinner MW, Curtis R, et al. Exploring regional variations in the cross-cultural, international implementation of the Patient Reported Outcomes Burdens and Experience (PROBE) study. Haemophilia 2019; 25(3): 365–72. doi: 10.1111/hae.13703.
- Skinner MW, Chai-Adisaksopha C, Curtis R, et al. The Patient Reported Outcomes, Burdens and Experiences (PROBE) Project: development and evaluation of a questionnaire assessing patient reported outcomes in people with haemophilia. Pilot Feasibility Stud 2018; 4: 58. doi: 10.1186/s40814-018-0253-0.
- Gusi N, Olivares PR, Rajendram R. The EQ-5D health-related quality of life questionnaire. In: Preedy VR, Watson RR (eds) Handbook of Disease Burdens and Quality of Life Measures. New York, NY: Springer; 2010: 87–99. doi: 10.1007/978-0-387-78665-0_5.
- Van Genderen FR, van Meeteren NL, van der Bom JG, et al. Functional consequences of haemophilia in adults: the development of the Haemophilia Activities List. Haemophilia 2004; 10(5): 565–71. doi: 10.1111/j.1365-2516.2004.01016.x.
- Van Genderen FR, Westers P, Heijnen L, et al. Measuring patients' perceptions on their functional abilities: validation of the Haemophilia Activities List. Haemophilia 2006; 12(1): 36–46. doi: 10.1111/j.1365-2516.2006.01186.x.
- Porter ME, Larsson S, Lee TH. Standardizing patient outcomes measurement. N Engl J Med 2016; 374(6): 504–506. doi: 10.1056/NEJMp1511701.
- Albrecht G, Devlieger P. The disability paradox: high quality of life against all odds. Soc Sci Med 1999; 48: 977–88. doi: 10.1016/s0277-9536(98)00411-0.
- eProvide. Search [database; search term “hemophilia”]. Available from https://eprovide.mapi-trust.org/search?form%5Bsearch-Text%5D=hemophilia&form%5BfromAutocomplete%5D=0&-form%5BsortByOrder%5D=&form%5Bpage%5D=1&form%5Bezxform_token%5D=U0MQXw_4nnrly2pvFc5mV-AxTqQrd-8sE-qMmq5XCQhA (accessed 14 April 2020).
- Iorio A, Skinner MW, Clearfield E, et al. Core outcome set for gene therapy in haemophilia: results of the coreHEM multistakeholder project. Haemophilia 2018; 24(4): e167–e172. doi: 10.1111/hae.13504.
- Morel T, Cano SJ. Measuring what matters to rare disease patients–reflections on the work by the IRDiRC taskforce on patient-centered outcome measures. Orphanet J Rare Dis 2017; 12(1): 171. doi: 10.1186/s13023–017-0718-x.